Risk factors

Cardiff Oncology is a clinical-stage biotech focused on its sole product candidate, onvansertib, which requires substantial additional capital to develop.

Crinetics is a clinical-stage biopharmaceutical company developing paltusotine and atumelnant for rare endocrine diseases and tumors.

Cronos Group faces risks primarily driven by early-stage operations, market uncertainties in Israel, raw material dependency on Cronos GrowCo, and regulatory hurdles in the cannabis sector.

Medicare and a commercial payor dominate revenue, contributing 47% and 15% respectively in 2024. Tests like DecisionDx-Melanoma and TissueCypher drive current financial performance. Growth relies heavily on securing reimbursement, clinician adoption, and navigating complex laboratory regulations.

CSX faces heavy regulatory oversight from bodies like the STB, FRA, and EPA impacting operations. The company is bound by common carrier mandates to transport hazardous materials, creating accident and security risks. Labor relations, network constraints, and severe weather threaten operational efficiency and volume.

Demand depends heavily on volatile natural resource commodities and customer capital spending in Canada and Australia. High geographic concentration in the oil sands of Alberta and the Bowen and Pilbara basins in Australia. Substantial debt and foreign currency exposure between the U.S. dollar and the Australian and Canadian dollars.

California Water Service Group is heavily dependent on state and federal regulatory approvals to recover infrastructure and operating costs.

Virginia’s zero-carbon requirements and Dominion’s 2050 net-zero commitment drive major compliance and investment risks.

DocGo faces intense regulatory and reimbursement scrutiny in its medical transportation and mobile health businesses. Revenue heavily relies on government contracts and a small number of key customers. Labor costs, recruitment of healthcare professionals, and integration of past acquisitions dominate risk factors.

Heavy reliance on debt including a $250.0 million term loan and $200.0 million revolving credit facility maturing in July 2027. Substantial concentration of sales to major customers including Boeing, Spirit, and Viasat in cyclical aerospace and defense markets. Exposure to U.S. government defense spending, DCAA audits, and strict export control regulations for facilities like Guaymas, Mexico.

The company relies heavily on subscription revenue from healthcare commercial intelligence platforms and data feeds. Operations face intense competition, data access dependencies, and profitability hurdles with significant net losses. Regulatory, privacy, and artificial intelligence integration risks could harm reputation and growth.

Denali is a clinical-stage biopharmaceutical company with an accumulated deficit of $1.54 billion as of December 31, 2024. Operations depend heavily on the proprietary TV platform and collaborations with Biogen, Sanofi, Takeda, and others.